Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 34Gastrointestinal 28Thoracic 26Other hematologic neoplasm 23Genitourinary 20Head & Neck 16Other solid neoplasm 14Gynecologic 12Tumor-Agnostic 9Lymphoid 8Dermatologic 7CNS 6Plasma cell 5Sarcoma 3Other 2Myeloid 2Other neoplasm 1Endocrine 1Classical hematology 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Practice Guidelines as Topic × Endocrine × Clear all
NCT04032106 2025-03-14

HPV Vaccine Intervention for Young Sexual Minority Men

Ohio State University Comprehensive Cancer Center

Phase NA Completed
1,227 enrolled 8 charts
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡